Skip to main content

Articles

Page 1 of 15

  1. South Africa has the highest number of people with HIV (PWH) globally and a significant burden of co-occurring substance use disorder (SUD). Health care worker (HCW) stigma towards SUD is a key barrier to HIV ...

    Authors: Jessica F. Magidson, Alexandra L. Rose, Kristen S. Regenauer, Carrie Brooke-Sumner, Morgan S. Anvari, Helen E. Jack, Kim Johnson, Jennifer M. Belus, John Joska, Ingrid V. Bassett, Goodman Sibeko and Bronwyn Myers
    Citation: Addiction Science & Clinical Practice 2022 17:52
  2. Women with co-occurring posttraumatic stress disorder (PTSD) and substance use disorder (SUD) experience systemic barriers that place them in danger of poorer treatment outcomes. Some mindfulness-based interve...

    Authors: Vanessa C. Somohano, Josh Kaplan, Aurora G. Newman, Maya O’Neil and Travis Lovejoy
    Citation: Addiction Science & Clinical Practice 2022 17:51
  3. People with opioid use disorder (OUD) face barriers to entering and remaining in life-saving treatment (e.g., stigma, detrimental interactions with health care, and privacy concerns). Telehealth and related te...

    Authors: Jordon D. Bosse, Kim Hoffman, Katharina Wiest, P. Todd Korthuis, Ritwika Petluri, Kellie Pertl and Stephen A. Martin
    Citation: Addiction Science & Clinical Practice 2022 17:50
  4. There is an urgent need for interventions helping children affected by parental problematic alcohol consumption (PAC). Such interventions could target partners to individuals with PAC, partners who often thems...

    Authors: Ola Siljeholm, Philip Lindner, Magnus Johansson and Anders Hammarberg
    Citation: Addiction Science & Clinical Practice 2022 17:49
  5. People who inject drugs (PWID) have low rates of COVID-19 testing and vaccination and are vulnerable to severe disease. We partnered with a local, community-based syringe service program (SSP) in San Diego Cou...

    Authors: Angela R. Bazzi, Alicia Harvey-Vera, Tara Buesig-Stamos, Daniela Abramovitz, Carlos F. Vera, Irina Artamonova, Thomas L. Patterson and Steffanie A. Strathdee
    Citation: Addiction Science & Clinical Practice 2022 17:48
  6. Opioids are effective in pain-management, but long-term opioid users can develop prescription opioid use disorder (OUD). One treatment strategy in patients with OUD is rotating from a short-acting opioid to a ...

    Authors: Hannah Ellerbroek, Sandra A. S. van den Heuvel, Albert Dahan, Hans Timmerman, Cornelis Kramers and Arnt F. A. Schellekens
    Citation: Addiction Science & Clinical Practice 2022 17:47
  7. Post-traumatic stress disorder (PTSD) and substance use disorders (SUDs) often co-occur in adolescent patients. Previous research has shown that these patients differ from SUD patients without PTSD in terms of...

    Authors: Lukas Andreas Basedow, Melina Felicitas Wiedmann, Veit Roessner, Yulia Golub and Sören Kuitunen-Paul
    Citation: Addiction Science & Clinical Practice 2022 17:46
  8. Residential treatment is a common approach for treating opioid use disorder (OUD), however, few studies have directly compared it to outpatient treatment. The objective of this study was to compare OUD outcome...

    Authors: Daniel M. Hartung, Sheila Markwardt, Kirbee Johnston, Jonah Geddes, Robin Baker, Gillian Leichtling, Christi Hildebran, Brian Chan, Ryan R. Cook, Dennis McCarty, Udi Ghitza and P. Todd Korthuis
    Citation: Addiction Science & Clinical Practice 2022 17:45
  9. Psychosocial interventions are needed to enhance patient engagement and retention in medication treatment within opioid treatment programs. Measurement-based care (MBC), an evidence-based intervention structur...

    Authors: Kelli Scott, John Guigayoma, Lawrence A. Palinkas, Francesca L. Beaudoin, Melissa A. Clark and Sara J. Becker
    Citation: Addiction Science & Clinical Practice 2022 17:44
  10. Medications for opioid use disorder (MOUDs), including methadone, buprenorphine, and naltrexone, decrease mortality and morbidity for people with opioid use disorder (OUD). Buprenorphine and methadone have the...

    Authors: Barbara Andraka-Christou, Cory Page, Victoria Schoebel, Jessica Buche and Rebecca L. Haffajee
    Citation: Addiction Science & Clinical Practice 2022 17:43
  11. As a public health issue, non-fatal overdose (NFOD) is highly prevalent among people who inject drugs (PWID). This can lead to an elevated risk of future overdose, causing various harms including possible deat...

    Authors: Bahram Armoon, Mark D. Griffiths, Azadeh Bayani, Rasool Mohammadi and Elaheh Ahounbar
    Citation: Addiction Science & Clinical Practice 2022 17:42
  12. In an effort to address the current opioid epidemic, a number of hospitals across the United States have implemented emergency department-based interventions for engaging patients presenting with opioid use di...

    Authors: Dennis P. Watson, Monte D. Staton and Nicole Gastala
    Citation: Addiction Science & Clinical Practice 2022 17:41
  13. People with opioid use disorder experience high burden of disease from medical comorbidities and are increasingly hospitalized with medical complications. Medications for opioid use disorder are an effective, ...

    Authors: Allison J. Ober, Cristina Murray-Krezan, Kimberly Page, Peter D. Friedmann, Karen Chan Osilla, Stephen Ryzewicz, Sergio Huerta, Mia W. Mazer, Isabel Leamon, Gabrielle Messineo, Katherine E. Watkins, Teryl Nuckols and Itai Danovitch
    Citation: Addiction Science & Clinical Practice 2022 17:39
  14. To characterize and address the opioid crisis disproportionately impacting rural U.S. regions.

    Authors: Richard A. Jenkins, Bridget M. Whitney, Robin M. Nance, Todd M. Allen, Hannah L. F. Cooper, Judith Feinberg, Rob Fredericksen, Peter D. Friedmann, Vivian F. Go, Wiley D. Jenkins, P. Todd Korthuis, William C. Miller, Mai T. Pho, Abby E. Rudolph, David W. Seal, Gordon S. Smith…
    Citation: Addiction Science & Clinical Practice 2022 17:38
  15. Internet-delivered cognitive behavioral therapy (ICBT) for alcohol misuse has potential to radically improve access to evidence-based care, and there is a need to investigate ways to optimize its delivery in c...

    Authors: Christopher Sundström, Vanessa Peynenburg, Carly Chadwick, David Thiessen, Andrew Wilhems, Marcie Nugent, Matthew T. Keough, Michael P. Schaub and Heather D. Hadjistavropoulos
    Citation: Addiction Science & Clinical Practice 2022 17:37
  16. The opioid antagonist extended-release naltrexone (XR-NTX) in the treatment of opioid use disorder (OUD) is effective in terms of safety, abstinence from opioid use and retention in treatment. However, it is u...

    Authors: Anne Marciuch, Ida Halvorsen Brenna, Bente Weimand, Kristin Klemmetsby Solli, Lars Tanum, Bente K. Røstad and Bente Birkeland
    Citation: Addiction Science & Clinical Practice 2022 17:36
  17. Though methadone has been shown to effectively treat opioid use disorder, many barriers prevent individuals from accessing and maintaining treatment. Barriers are prevalent in less populated areas where treatm...

    Authors: Emily Pasman, Rachel Kollin, Michael Broman, Guijin Lee, Elizabeth Agius, Jamey J. Lister, Suzanne Brown and Stella M. Resko
    Citation: Addiction Science & Clinical Practice 2022 17:35
  18. Opioid use disorder (OUD) is a serious health condition that is effectively treated with buprenorphine. However, only a minority of people with OUD are able to access buprenorphine. Many access points for bupr...

    Authors: Caleb J. Banta-Green, Mandy D. Owens, Jason R. Williams, Jeanne M. Sears, Anthony S. Floyd, Wendy Williams-Gilbert and Susan Kingston
    Citation: Addiction Science & Clinical Practice 2022 17:34
  19. Despite demonstrated efficacy, medication treatment for opioid use disorder (MOUD) remain inaccessible to many patients, with barriers identified at the individual, clinic and system level. A wide array of imp...

    Authors: Jessica J. Wyse, Katherine Mackey, Travis I. Lovejoy, Devan Kansagara, Anais Tuepker, Adam J. Gordon, P. Todd Korthuis, Anders Herreid-O’Neill, Beth Williams and Benjamin J. Morasco
    Citation: Addiction Science & Clinical Practice 2022 17:32
  20. Pregaming is a high-drink context popular among college students that often leads to elevated blood alcohol levels and negative consequences. Over 15 years of research studies have demonstrated that pregaming ...

    Authors: Eric R. Pedersen, Justin F. Hummer, Jordan P. Davis, Reagan E. Fitzke, Nina C. Christie, Katie Witkiewitz and John D. Clapp
    Citation: Addiction Science & Clinical Practice 2022 17:31
  21. Until recently, few carceral facilities offered medications for opioid use disorder (MOUD). Although more facilities are adopting MOUD, much remains to be learned about addressing implementation challenges rel...

    Authors: Noa Krawczyk, Sachini Bandara, Sydney Merritt, Hridika Shah, Alexandra Duncan, Brendan McEntee, Maria Schiff, N. Jia Ahmad, Sara Whaley, Amanda Latimore and Brendan Saloner
    Citation: Addiction Science & Clinical Practice 2022 17:30
  22. A cessation program for hospitalized smokers is an effective strategy to achieve smoking abstinence. The effects of multiple in-hospital counseling sessions on 6-month smoking abstinence require further invest...

    Authors: Chin-Wei Kuo, Chuan-Yu Chen, Chih-Hsing Wu, Chang-Wen Chen, Fei-Ran Guo and Szu-Chun Yang
    Citation: Addiction Science & Clinical Practice 2022 17:29
  23. The 2016 U.S. Centers for Disease Control Opioid Prescribing Guideline (CDC Guideline) is currently being revised amid concern that it may be harmful to people with chronic pain on long-term opioid therapy (CP...

    Authors: Gabriela Cedillo, Mary Catherine George, Richa Deshpande, Emma K. T. Benn, Allison Navis, Alexandra Nmashie, Alina Siddiqui, Bridget R. Mueller, Yosuke Chikamoto, Linda Weiss, Maya Scherer, Alexandra Kamler, Judith A. Aberg, Barbara G. Vickrey, Angela Bryan, Brady Horn…
    Citation: Addiction Science & Clinical Practice 2022 17:28
  24. Subcutaneously retained needle fragments in people who inject drugs (PWIDs) are a possible cause of local symptoms, most commonly pain and infections. It remains unknown how common retained needle fragments ar...

    Authors: Heidi Laukkala, Otso Arponen, Mika O Murto and Olli PO Nevalainen
    Citation: Addiction Science & Clinical Practice 2022 17:27
  25. Social networks may play positive and negative roles in the lives of young adults experiencing homelessness (YEH) who are transitioning into housing. Social networks can influence their alcohol and/or other dr...

    Authors: David P. Kennedy, Karen Chan Osilla and Joan S. Tucker
    Citation: Addiction Science & Clinical Practice 2022 17:26
  26. Drug overdose rates in the United States have been steadily increasing, particularly in rural areas. The COVID-19 pandemic and associated mitigation strategies may have increased overdose risk for people who u...

    Authors: Suzan M. Walters, Rebecca S. Bolinski, Ellen Almirol, Stacy Grundy, Scott Fletcher, John Schneider, Samuel R. Friedman, Lawrence J. Ouellet, Danielle C. Ompad, Wiley Jenkins and Mai T. Pho
    Citation: Addiction Science & Clinical Practice 2022 17:24
  27. Opioid use disorders (OUD), co-occurring with either depression and/or PTSD, are prevalent, burdensome, and often receive little or low-quality care. Collaborative care is a service delivery intervention that ...

    Authors: Karen Chan Osilla, Alex R. Dopp, Katherine E. Watkins, Venice Ceballos, Brian Hurley, Lisa S. Meredith, Isabel Leamon, Vanessa Jacobsohn and Miriam Komaromy
    Citation: Addiction Science & Clinical Practice 2022 17:25
  28. Aboriginal and Torres Strait Islander (‘Indigenous’) Australians experience a greater burden of disease from alcohol consumption than non-Indigenous peoples. Brief interventions can help people reduce their co...

    Authors: James H. Conigrave, K. S. Kylie Lee, Paul S. Haber, Julia Vnuk, Michael F. Doyle and Katherine M. Conigrave
    Citation: Addiction Science & Clinical Practice 2022 17:23
  29. An increasing number of individuals who use drugs in North America are preferentially consuming fentanyl over other opioids. This has significant consequences on the treatment and management of opioid use diso...

    Authors: Pouya Azar, Jean N. Westenberg, Martha J. Ignaszewski, James S. H. Wong, George Isac, Nickie Mathew and R. Michael Krausz
    Citation: Addiction Science & Clinical Practice 2022 17:22
  30. Authors: Joanne G. Patterson, Tia N. Borger, Jessica L. Burris, Mark Conaway, Robert Klesges, Amie Ashcraft, Lindsay Hauser, Connie Clark, Lauren Wright, Sarah Cooper, Merry C. Smith, Mark Dignan, Stephenie Kennedy-Rea, Electra D. Paskett, Roger Anderson and Amy K. Ferketich
    Citation: Addiction Science & Clinical Practice 2022 17:21

    The original article was published in Addiction Science & Clinical Practice 2022 17:11

  31. Alcohol use increases risk for morbidity and mortality and is associated with over 3 million annual deaths worldwide. Contingency Management (CM) is one of the most effective interventions for substance use di...

    Authors: Crystal L. Smith, Nicole M. Rodin, Julie Y. Hwang, André Q. C. Miguel, Kim Johnson, Michael G. McDonell and Sterling M. McPherson
    Citation: Addiction Science & Clinical Practice 2022 17:20
  32. Alcohol use is a significant risk factor for disability and death in U.S. adults, and approximately one out of every six Veterans seen in primary care (PC) report unhealthy alcohol use. Unhealthy alcohol use i...

    Authors: Rachel L. Bachrach, Matthew Chinman, Keri L. Rodriguez, Maria K. Mor, Kevin L. Kraemer, Cécile E. Garfunkel and Emily C. Williams
    Citation: Addiction Science & Clinical Practice 2022 17:19
  33. The present study aimed to evaluate the results of a theory-based and systematic intervention on Hookah Tobacco Smoking (HTS) cessation in women local to Bandar Abbas, Iran.

    Authors: Sakineh Dadipoor, Ali Heyrani, Mehdi Mirzaei-Alavijeh, Teamur Aghamolaei, Mohtasham Ghaffari and Amin Ghanbarnejad
    Citation: Addiction Science & Clinical Practice 2022 17:18
  34. Disadvantage and transgenerational trauma contribute to Aboriginal and Torres Strait Islander (Indigenous) Australians being more likely to experience adverse health consequences from alcohol and other drug us...

    Authors: James H. Conigrave, Scott Wilson, Katherine M. Conigrave, Tanya Chikritzhs, Noel Hayman, Angela Dawson, Robert Ali, Jimmy Perry, Michelle S. Fitts, Louisa Degenhardt, Michael Doyle, Sonya Egert, Tim Slade, Nadine Ezard, Monika Dzidowska and K. S. Kylie Lee
    Citation: Addiction Science & Clinical Practice 2022 17:17
  35. Morbidity and mortality related to opioid use disorder (OUD) in the U.S. is at an all-time high. Innovative approaches are needed to address gaps in retention in treatment with medications for opioid use disor...

    Authors: Jacqueline Hodges, Marika Waselewski, William Harrington, Taylor Franklin, Kelly Schorling, Jacqueline Huynh, Alexa Tabackman, Kori Otero, Karen Ingersoll, Nassima Ait-Daoud Tiouririne, Tabor Flickinger and Rebecca Dillingham
    Citation: Addiction Science & Clinical Practice 2022 17:16
  36. Medication treatment for opioid use disorder (OUD) (MOUD; buprenorphine and methadone) reduces opioid use and overdose. Discontinuation of MOUD can quickly lead to relapse, overdose and death. Few persons who ...

    Authors: Breanne E. Biondi, Brent Vander Wyk, Esther F. Schlossberg, Albert Shaw and Sandra A. Springer
    Citation: Addiction Science & Clinical Practice 2022 17:15
  37. The prevalence of alcohol use disorder (AUD) among women in South Korea has been rising, causing public health problems. Yet women’s treatment needs are mostly unmet in South Korea due to the lack of women-foc...

    Authors: Insuk Lee, Mihyoung Lee and Scott Seung W. Choi
    Citation: Addiction Science & Clinical Practice 2022 17:14
  38. We have previously shown that service-wide support can increase the odds of alcohol screening in any 2-month period in a cluster randomized trial of service-wide support to Aboriginal and Torres Strait Islande...

    Authors: Monika Dzidowska, Jacques E. Raubenheimer, Timothy A. Dobbins, K. S. Kylie Lee, Noel Hayman, Julia Vnuk, Paul Haber and Katherine M. Conigrave
    Citation: Addiction Science & Clinical Practice 2022 17:13
  39. The cervical cancer burden is high among women living in Appalachia. Cigarette smoking, a cervical cancer risk factor, is also highly prevalent in this population. This project aims to increase smoking cessati...

    Authors: Joanne G. Patterson, Tia N. Borger, Jessica L. Burris, Mark Conaway, Robert Klesges, Amie Ashcraft, Lindsay Hauser, Connie Clark, Lauren Wright, Sarah Cooper, Merry C. Smith, Mark Dignan, Stephenie Kennedy-Rea, Electra D. Paskett, Roger Anderson and Amy K. Ferketich
    Citation: Addiction Science & Clinical Practice 2022 17:11

    The Correction to this article has been published in Addiction Science & Clinical Practice 2022 17:21

  40. Substance use disorders, depression and anxiety disproportionately affect people with HIV (PWH) and lead to increased morbidity and mortality. Routine screening can help address these problems but is underutil...

    Authors: Alexandra N. Lea, Andrea Altschuler, Amy S. Leibowitz, Tory Levine-Hall, Jennifer McNeely, Michael J. Silverberg and Derek D. Satre
    Citation: Addiction Science & Clinical Practice 2022 17:10
  41. Alcohol use disorder (AUD) is one of the leading etiologies for liver cirrhosis and liver transplantation. Few individuals with AUD receive guideline-based care in the form of screening, brief intervention, re...

    Authors: Emily Johnson, Sumantra Monty Ghosh, Vijay John Daniels, T. Cameron Wild, Puneeta Tandon and Ashley Hyde
    Citation: Addiction Science & Clinical Practice 2022 17:9
  42. Interventions are needed to improve the quality of South Africa’s substance use disorder (SUD) treatment system. This study aimed to identify factors associated with patient-reported suboptimal access, quality...

    Authors: Bronwyn Myers, J. Randy Koch, Kim Johnson and Nadine Harker
    Citation: Addiction Science & Clinical Practice 2022 17:8
  43. To address the US opioid epidemic, there is an urgent clinical need to provide persons with opioid use disorder (OUD) with effective medication treatments for OUD (MOUD). Formulations of sublingual buprenorphi...

    Authors: Ismene Petrakis, Sandra A. Springer, Cynthia Davis, Elizabeth Ralevski, Lucy Gu, Robert Lew, John Hermos, Melynn Nuite, Adam J. Gordon, Thomas R. Kosten, Edward V. Nunes, Robert Rosenheck, Andrew J. Saxon, Robert Swift, Alexa Goldberg, Robert Ringer…
    Citation: Addiction Science & Clinical Practice 2022 17:6
  44. Medications to treat opioid use disorder (OUD) including buprenorphine products are evidence-based and cost-effective tools for combating the opioid crisis. However, limited availability to buprenorphine is pe...

    Authors: Kevin P. Conway, Dalia Khoury, Rainer Hilscher, Arnie P. Aldridge, Stephanie J. Parker and Gary A. Zarkin
    Citation: Addiction Science & Clinical Practice 2022 17:5
  45. Extended-release buprenorphine (XRB) offers a novel approach to sustained monthly treatment for people who use opioids in criminal justice settings (CJS). This study explores the experiences of adults receivin...

    Authors: Anna Cheng, Ryan Badolato, Andrew Segoshi, Ryan McDonald, Mia Malone, Kumar Vasudevan, Beita Badiei, Allison Sugarman, Ross Macdonald, Jasdeep Mangat, Jonathan Giftos, Joshua D. Lee and Babak Tofighi
    Citation: Addiction Science & Clinical Practice 2022 17:4
  46. A quarter of pregnant women use alcohol, 6.5/1000 deliveries are affected by opioid use disorder (OUD), and the prevalence of cannabis use in pregnant women is increasing. However, marijuana co-exposure in pol...

    Authors: Kimberly Page, Cristina Murray-Krezan, Lawrence Leeman, Mary Carmody, Julia M. Stephen and Ludmila N. Bakhireva
    Citation: Addiction Science & Clinical Practice 2022 17:3

Affiliated with

Annual Journal Metrics

Archival content

Addiction Science & Clinical Practice was formerly published by NIDA and previous issues of the journal can be viewed here.